This review (2015) describes the immunomodulatory potential of classical serotonergic psychedelics (DMT, LSD, MDMA, etc) from a perspective of molecular immunology and pharmacology. With a particular focus on functional interaction of serotonin and sigma-1 receptors and cross-talk with toll-like and RIG-I-like pattern-recognition receptor-mediated signalling.
Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular proliferation, and cell survival via activating NF-κB and mitogen-activated protein kinases. Recently, several neurotransmitter receptors involved in the pharmacology of psychedelics, such as serotonin and sigma-1 receptors, have also been shown to play crucial roles in numerous immunological processes. This emerging field also offers promising treatment modalities in the therapy of various diseases including autoimmune and chronic inflammatory conditions, infections, and cancer. However, the scarcity of available review literature renders the topic unclear and obscure, mostly posing psychedelics as illicit drugs of abuse and not as physiologically relevant molecules or as possible agents of future pharmacotherapies. In this paper, the immunomodulatory potential of classical serotonergic psychedelics, including N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-iodoamphetamine, and 3,4-methylenedioxy-methamphetamine will be discussed from a perspective of molecular immunology and pharmacology. Special attention will be given to the functional interaction of serotonin and sigma-1 receptors and their cross-talk with toll-like and RIG-I-like pattern-recognition receptor-mediated signaling. Furthermore, novel approaches will be suggested feasible for the treatment of diseases with chronic inflammatory etiology and pathology, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, schizophrenia, depression, and Alzheimer’s disease.
Papers cited by this study that are also in Blossom
Tracy, D., Baumeister, D., Barnes, G. et al. · Therapeutic Advances in Psychopharmacology (2014)
Alper, K. · The Alkaloids Chemistry and Biology (2001)
Hayashi, T., Vaupel, D. B., Su, T. P. · Science Signaling (2009)
Schenberg, E. E. · Sage Open Medicine (2013)
Barker, S., McIlhenny, E. H., Strassman, R. J. · Drug Testing and Analysis (2012)
Psychedelics are psychoactive compounds that alter perception and cognition primarily via neurotransmitter receptors, most notably serotonergic 5-HT receptor subtypes. Hohlfeld and colleagues frame classical psychedelics (tryptamines, lysergamides, phenethylamines) as agents that, beyond psychopharmacology, may influence immune function because many immune cells express neurotransmitter receptors and participate in neuroimmune communication. The introduction notes that early work on psychedelics and immunity dates from the 1970s, but systematic biomedical interest has only resurged in the past decade, and rigorous evidence on immunomodulatory actions remains limited. The paper sets out to review and synthesise molecular immunology and pharmacology evidence for the immunomodulatory potential of classical serotonergic psychedelics, including DMT, 5-MeO-DMT, LSD, DOI and MDMA, with particular attention to serotonin and sigma-1 receptor biology and their cross-talk with pattern-recognition receptor (PRR) signalling. Hohlfeld and colleagues aim to propose mechanistic models and suggest novel therapeutic approaches for conditions with chronic inflammatory or autoimmune pathology, while highlighting gaps in the literature and translational hurdles.
The extracted text presents a narrative, mechanistic review rather than reporting a new experiment or a formal systematic review. The authors synthesise molecular and cellular studies (in vitro and some in vivo animal and human observations) to develop conceptual models of how serotonergic psychedelics and sigma-1 receptor ligands may alter immune signalling. Key topics addressed include 5-HT receptor and sigma-1 receptor signalling, innate PRR pathways (TLRs and RLRs) and downstream NF-κB/IRF/MAPK cascades, and evidence from studies of specific compounds (DMT, 5-MeO-DMT, LSD, DOI, MDMA). The extracted text does not clearly report any explicit literature search strategy, databases searched, inclusion/exclusion criteria, or formal risk-of-bias assessment; therefore it appears to be a narrative synthesis drawing on selected primary studies and reviews. Where experimental findings are cited, the paper often refers to in vitro primary cell culture work, animal studies, and limited human observations (for example, immunological changes reported after ayahuasca consumption or MDMA use). Analytical approaches are conceptual and mechanistic rather than quantitative: the authors integrate receptor pharmacology, intracellular signalling pathways (G-proteins, PLC/IP3/Ca2+, PKC, PI3K/Akt, MAPKs, IKK/NF-κB, TBK1/IRF3/7) and PRR adaptor biology (MyD88, TRIF, MAVS) to propose models of cross-talk and signalling flux redistribution. The review also references systems-biology and non-linear network modelling concepts as tools for understanding emergent properties of signalling networks.
The review summarises molecular features of 5-HT (serotonin) receptor subtypes and the sigma-1 receptor that are relevant to immune regulation. 5-HT1A receptors signal largely via Gαi pathways affecting adenylyl cyclase, PLC, Src, MAPKs and can influence NF-κB; 5-HT2A/2B/2C receptors couple to Gq-mediated PLC-β/IP3 pathways, increasing intracellular Ca2+, ERK MAPK activity and can engage Jak/STAT signalling. The sigma-1 receptor (sigmar-1) is localised at the endoplasmic reticulum–mitochondrion interface (MAM), can modulate Ca2+ channels and was identified as an endogenous target for DMT; sigmar-1 ligation releases it from BiP, enabling chaperone activity at IP3 receptors and enhancing Ca2+ signalling and ATP production. On innate immune sensing, the authors review PRR signalling through TLRs and RLRs which activate NF-κB, IRF3/7 and MAPKs via adaptors such as MyD88, TRIF and MAVS; downstream activation of TBK1 phosphorylates IRF3/7 to induce type I interferons, while cross-talk with NF-κB drives pro-inflammatory cytokines (IL-1β, IL-6, TNFα). The text emphasises that inappropriate activation of these pathways contributes to autoinflammatory and autoimmune disease. Evidence for psychedelic-mediated immunomodulation is presented for several compound classes. DMT and 5-MeO-DMT were reported to act via sigmar-1 in human monocyte-derived dendritic cell (moDC) cultures to inhibit secretion of inflammatory cytokines IL-1β, IL-6, TNFα and chemokine CXCL8/IL-8 while increasing anti-inflammatory IL-10; these treatments also impaired moDC-driven Th1 and Th17 CD4+ T-cell priming. DMT was additionally described as a non-competitive inhibitor of indoleamine 2,3-dioxygenase (IDO) and as an inducer of anti-tumour cytotoxicity in co-cultures of human peripheral blood mononuclear cells (PBMCs) and a glioma cell line. Ayahuasca consumption (a complex DMT-containing brew) has been associated in cited studies with changes in lymphocyte subpopulations, notably an increase in circulating natural killer (NK) cells. Lysergamide (LSD) observations include in vitro reports that high concentrations (100 µM) inhibited B-cell proliferation and reduced secretion of IL-2, IL-4 and IL-6, and suppressed CD8+ cytotoxic T-lymphocyte (CTL) activation and NK responses. In contrast, low LSD concentrations (0.0001 and 0.1 µM) augmented NK cell function, a range reachable by recreational doses, suggesting dose-dependent, bidirectional immune effects. Among phenethylamines, DOI (a 5-HT2A agonist) was reported to block IL-1β and TNFα release by human PBMCs and to inhibit inducible nitric oxide synthase (iNOS) in glioma cells; notable work in rat primary aortic smooth muscle cells described DOI as a potent inhibitor of TNFα-induced inflammatory markers including ICAM-1, VCAM-1, IL-6, NOS activity and NF-κB signalling. MDMA studies cited show that low in vitro concentrations (0.0001–1.0 µM) increased mouse NK and T-helper activity, whereas acute in vivo administration produced immunosuppression by reducing lymphocyte proliferation and mitogen- or LPS-induced IL-1β and TNFα production. IL-10 was implicated as a critical mediator of MDMA’s immunosuppressive effects on IL-12 and IFNγ in murine models. Human observations reported both acute and chronic MDMA use to decrease T lymphocyte function and increase NK activity, with long-term use associated with reductions in total circulating lymphocyte numbers and alterations in plasma cytokines (decreased IL-2, increased TGF-β). At the mechanistic level, the paper highlights that psychedelics act principally via GPCR-coupled signalling (Gαq, Gαi, Gβγ) to regulate PLC/IP3/Ca2+, PKC, PI3K/Akt, MAPKs and NF-κB, thereby modulating cytokine production, antigen presentation and lymphocyte proliferation. The authors also cite meta-analyses suggesting serotonin signalling may mitigate type I interferon–mediated depressive symptoms in HCV patients, raising the possibility that chronic 5-HT receptor stimulation could interfere with PRR–IRF3/7 or type I IFN receptor pathways. Overall, reported effects are anti-inflammatory and, in some models, anti-tumour, but the authors note that anti-inflammatory/immunosuppressive actions could potentially conflict with anticancer immunity in vivo.
Hohlfeld and colleagues interpret the assembled evidence as indicating that classical psychedelics can exert anti-inflammatory and anti-cancer effects by modulating both innate and adaptive immune processes. They propose two complementary mechanistic models: (i) modulation of cytokine patterns, in which changes in levels of IL-10 and TGFβ versus TNFα and IFNγ reprogramme immune responses; and (ii) intracellular cross-talk between PRR pathways and 5-HTR/sigmar-1 signalling, mediated by shared downstream elements such as Ca2+, MAPKs and NF-κB, which could shift signalling outcomes and cellular fate decisions. The authors place these mechanistic proposals within a systems-biology perspective, arguing that stochastic single-cell signalling and network-level non-linear dynamics can produce emergent, population-level responses not apparent from single-cell analyses. They discuss the signalling-flux-redistribution (SFR) concept wherein perturbation of one adaptor or pathway (for example MyD88) redistributes signalling through alternative pathways (for example TRIF), and cite experimental validation of SFR using MyD88-/- and TRAF6-/- mice as illustrative of how network conservation principles might underlie observed cross-talk. Key limitations acknowledged in the text are the scarcity of direct experimental data supporting many of the proposed receptor–PRR interactions and the predominance of in vitro and animal studies rather than controlled human clinical trials. The authors emphasise that translational relevance remains uncertain and advocate further preclinical and clinical research to confirm mechanisms and therapeutic potential. As implications, they suggest that a deeper understanding of PRR–5-HTR/sigmar-1 cross-talk could inform novel immunopharmacotherapies for a broad range of chronic inflammatory, autoimmune and neuropsychiatric conditions; diseases specifically mentioned include atherosclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, multiple sclerosis, schizophrenia, depression and Alzheimer's disease. The discussion maintains a cautious tone, noting promise but underscoring the need for more comprehensive and translationally focused studies.
Psychedelics are psychoactive substances that possess the ability to alter cognition and perception by triggering neurotransmitter receptors in the brain. Psychedelics are members of a wider family of psychoactive drugs known as hallucinogens, a class that also includes essentially unrelated psychotropic substances (e.g., dissociatives, deliriants, etc.). These substances affect the mind in unique ways that result in altered states of consciousness, which are qualitatively and phenomenologically different from the ordinary states. According to their pharmacological action, psychedelics usually fall into one of the following categories: tryptamines, such as psilocin and N,N-dimethyltryptamine (DMT); lysergamides, most importantly lysergic acid diethylamide (LSD); phenethylamines, a large group of diverse substances including 2,5-dimethoxy-4-iodoamphetamine (DOI), and 3,4methylenedioxy-methamphetamine (MDMA); cannabinoids; and atypical psychedelics, such as salvinorin A. Tryptamines, lysergamides, and phenethylamines are often considered as "classical psychedelics" that exert their effects via the serotonergic system, and a growing body of evidence suggests that they may have therapeutic effects in treating many psychiatric disorders. Scientific investigations concerning the possible immunological effects of psychedelics date back to the early 70s. However, the biomedical Renaissance of psychedelic research has only begun about a decade ago. An important antecedent was the identification of neuro-immune communication in mammals that greatly expanded the domain of physiological activity of psychoactive substances. Since immune cells were found to also express many types of neurotransmitter receptors, an entirely new aspect was added to the biomedical paradigm. Early neuroimmunologists considered the immune and nervous systems as separate parts, but a crucial conceptual leap led to the emergence of the modern approach. This new concept represents neuroimmune communication as an integrated physiological entity with the immune and nervous systems being its two aspects. Many of the naturally occurring psychedelics have been used as a form of traditional medicine by indigenous people since centuries or even millennia. These remedies, as inherent parts of the shamanic practice, exert many beneficial effects on the human body. Unfortunately, the amount of evidence-based, rigorous scientific data about the immunomodulatory functions of psychedelic substances has been quite scarce to date. In the last two decades, several neurotransmitter receptors involved in the pharmacology of psychedelics have been identified as also being crucial in many immunological processes pointing out to novel therapeutic avenues. This emerging field offers very promising treatment modalities in the therapy of various diseases including autoimmune and chronic inflammatory conditions, infections, and cancer. However, the paucity of available review literature renders the topic unclear and obscure, mostly posing psychedelics as illicit drugs of abuse and not as possible and effective agents of future pharmacotherapies. In this paper, the immunomodulatory effects of classical serotonergic psychedelics will be discussed from a molecular immunological and pharmacological perspective, and novel approaches will be suggested in the treatment of various pathologies.
To understand the nature of the psychedelics-immunity crosstalk, we need to briefly discuss the molecular biology of neurotransmitter receptor pathways involved in the pharmacological actions of psychedelics. Classical psychedelics exhibit agonistic activity mainly at the 5-hydroxytryptamine (5-HT)/serotonin receptor 5-HT 1A and 5-HT 2A-C classes. These are G-proteincoupled receptors (GPCRs) with analogous biochemical architecture. Their intracellular domains contain sites for phosphorylation for diverse serine-threonine kinases mediating downstream signaling processes. The 5-HT 1A subtype primarily signals via G αi proteins activating or inhibiting adenylyl cyclase (AC), phospholipase C (PLC), Src kinase, mitogen-activated protein kinases (MAPKs), and several other effector pathways. It also induces the activity of nuclear factor-κB (NF-κB), a transcription factor that controls pro-inflammatory cytokine and chemokine gene expression (Figure). The 5-HT 2A receptor activates PLC-β leading to the accumulation of inositol phosphates and elevations of intracellular Ca 2+ in many tissues and cell types. It also has the capability to increase Cyclo-oxygenase-2 (COX-2) activity and the release of transforming growth factor beta (TGF-β) via the stimulation of ERK MAPK activity. Furthermore, ligated 5-HT 2A was shown to interact with the Janus kinase (Jak)/signal transducers and activators of transcription (STAT) pathway controlling a rapid tyrosine phosphorylation of Jak2 and STAT3 that leads to the nuclear translocation of STAT3. The human 5-HT 2B receptor has 45% structural homology with the 5-HT 2A and 42% homology with the 5-HT 2C subtypes. The functional 5-HT 2B protein is widely expressed not only in the brain but also in many peripheral tissues. In early studies, it has been showed that 5-HT 2B receptors can activate the Ras and ERK1/ERK2 MAPKs involving Gαq, G αi , and G βγ protein activities, and thereby modulate cellular proliferation and differentiation. Similarly to 5-HT 2A and 5-HT 2C receptors, the 5-HT 2B receptor couples to the PLC-inositol 1,4,5-trisphosphate (IP 3 ) system directly controlling the release of Ca 2+ from intracellular stores (Figure). The ligation of 5-HT 1 and 5-HT 2 receptors can directly alter cellular functions in immune cells. In an important study, 5-HT 1 and 5-HT 2 receptor stimulation was shown to induce intracellular Ca 2+ mobilization via G αi proteins in resting, but not lipopolysaccharide (LPS) activated DCs. The 5-HT 2C receptor has also been shown to modulate PLC-IP 3 activity (28), and has recently been described as indispensable for the serotonin-mediated activation of murine alveolar macrophages. Interestingly, the 5-HT 1 and 5-HT 2 receptors have a high expression profile in mammalian lymphoid tissues and involved in many immunological processes. These include antitumor and anti-viral immune responses, and the neuroendocrine regulation of inflammation via serotonin as a key factor in immune homeostasis. The sigma-1 receptor (Sig-1R or sigmar-1) is a small integral membrane protein consisting of a short N-terminus, a large Cterminus tail, and two transmembrane domains. Sigmar-1 localizes at the endoplasmic reticulum (ER)-mitochondrion interface, also called mitochondria-associated ER membrane (MAM). Previous studies have shown that sigmar-1 interacts with numerous cellular components, such as GPCRs and ion channels (e.g., Na + , K + , and Ca 2+ ). Importantly, similar to 5-HT receptors (5-HTRs), sigmar-1 can also enhance or block the activity of Ca 2+ channels and thereby regulate intracellular Ca 2+ levels. Recently, DMT has been identified as a natural, endogenous ligand for sigmar-1. Ligation by DMT causes the dissociation of sigmar-1 from binding immunoglobulin protein (BiP), allowing it to act as a molecular chaperone to IP 3 receptors. This activation leads to enhanced Ca 2+ signaling and a significant increase in the production of adenosine triphosphate (Figure). Although it resides primarily at the ER, sigmar-1 directly translocates from the MAM to the plasma membrane or the subplasma membrane area following its activation by higher concentrations of specific ligands or when the receptor is overexpressed in cells. This may explain why the concentration of DMT-modulating cellular physiology is almost 10-fold as compared to its affinity concentration. Early studies demonstrated that sigmar-1 is expressed not only in distinct regions of the CNS but also in immune cells. Murine studies also showed that the specific activation of sigmar-1 resulted in immunosuppression, and in vivo decreased lymphocyte activation and proliferation. Sigma-1 receptor ligands possess potent immunoregulatory properties via increasing the secretion level of anti-inflammatory IL-10 (52), and suppressing interferon (IFN)γ and GM-CSF expression.
The immune system acts as an evolutionally conserved and advanced host defense mechanism against invading pathogens. Innate immune responses are triggered by phylogenetically conserved microbial components that are essential for the survival of a given type of organism. Upon pathogenic infection, these pathogen-associated molecular patterns (PAMPs) are recognized by specific pattern-recognition receptors (PRRs) that are germline encoded and are usually expressed constitutively in the host. The overall picture, however, is far more complex as successful microbial moieties are also found in non-pathogenic microbes, and thus the presence of different PAMPs per se is not sufficient to discriminate "pathogenic" and "non-pathogenic" microbial taxa. Furthermore, certain PRRs also sense host-derived/"self " components that become available as a result of cellular/tissue injury. The list of these endogenous damage-associated molecular patterns (DAMPs) is continuously growing but their impact on immune homeostasis is yet to be clarified (Figuresand). Thus far, five classes of PRRs have been identified. Two important classes are: (i) transmembrane toll-like receptors (TLRs), which are integrated to cell surface or endosomal membranes of various cell types; (ii) cytosolic RIG-I-like receptors (RLRs). Upon binding of their specific ligands, these PRRs activate the NF-κB and the IFN-regulatory factor 3/7 (IRF3/7) pathways, as well as MAPKs, such as p38, ERK1/2, and c-Jun N-terminal kinase (JNK). This process altogether results in the expression of a common set of genes whose products, such as inflammatory cytokines, chemokines, and co-stimulatory molecules, are essential for the orchestration of both innate and adaptive immunity (Figure). TLR and RLR ligation results in the activation of myeloid differentiation primary response gene 88 (MyD88) or the TIR-domain-containing adapter-inducing IFN-β (TRIF) adapter proteins for TLR pathways, and the mitochondrial adapter mitochondrial anti-viral-signaling protein (MAVS) that mediates RLR downstream signaling. TRIF and MAVS then couple to the TNF receptor-associated factor 3 (TRAF3) conveying the signal to TANK-binding kinase 1 (TBK1) through TRAF family-memberassociated NF-κB activator (TANK) binding. Activated TBK1 induces the phosphorylation of IRF3/IRF7 on specific serine residues, resulting in their homodimerization. These dimers then translocate to the nucleus inducing the transcription of type I IFN genes, a cytokine family that is highly involved in anti-viral and anti-tumor immunity (Figure). This pathway is implicated to be connected to the NF-κB activation pathway through the interaction of FAS-associated via death domain (FADD), Receptor-interacting protein (RIP1) and TRAF6, which result in the induction of pro-inflammatory cytokine genes and proteins, such as IL-1β, IL-6, and TNF-α. The activation of these pathways are crucial in anti-pathogenic immune responses, but are also involved in autoinflammatory and autoimmune pathologies where undesirable inflammation causes chronic and severe damage to self tissues.
Many of the classical psychedelics have the capability to interfere with both innate and adaptive immunity. This modulatory potential is usually manifested through the inhibition of inflammatory responses and antigen presentation, and specific, disparate regulation of the proliferation and function of certain lymphocyte subtypes, such as cytotoxic T-lymphocytes (CTLs) or NK cells. The receptors involved in the pharmacology of classical psychedelics are mainly expressed by neuronal cells, and their function in the CNS is well described. However, they are also expressed by immune and hematopoietic cells, and the details of their modulatory potential have not been elucidated yet. Regrettably, we have a very limited understanding of these neuroimmune signaling events thus far. The cross-talk between immune sensors and receptors involved in the pharmacology of psychedelics may occur at multiple levels. Two possible ways of this communication will be proposed. First, an inter-cellular interaction may be established by means of cytokine regulation among various immune cell and tissue types. The classical psychedelics discussed in this paper are acting at either one or all of the 5-HT 1A , 5-HT 2A , 5-HT 2B , and 5-HT 2C serotonin receptor subtypes. The activation of these 5-HTR subtypes displays an unique effect on the production of cytokines, which has similar immunological functions, such as IL-1β and TNFα. 5-HT receptor activation results in a decrease of TNFα, but an increase in IL-1β secretion in human peripheral blood mononuclear cells (PBMCs), DCs, and monocytes stimulated with PRR ligands. Furthermore, serotonin was shown to facilitate the production of the pro-inflammatory IL-16 and IFNγ by activated CTLs and NK cells. Thus 5-HT receptor agonism appears to control the inflammatory response by regulating different patterns of cytokine secretion. Additionally, another key factor here is the negative feedback regulation of inflammation via the induction of the release of antiinflammatory IL-10 and TGFβ occurring subsequent of 5-HT 1 and 5-HT 2 receptor activation (Figure). Second, 5-HTR activation, besides its influence on the complex cytokine-feedback regulation, may also interfere with the chemokine, inflammatory cytokine, and/or type I IFN receptor signaling of immune cells through intracellular mechanisms. Most of the receptors that are involved in psychedelic effects belong to the GPCR family or interact with GPCRs (e.g., sigmar-1). The role of 5-HTR/GPCR-coupled signals in the intracellular regulation and orchestration of NF-κB, type I IFN, and MAPK pathways may be of particular importance regarding the complex immunological effects of psychedelics. GPCR agonists have already been described as potent inducers of cytokines, adhesion molecules, and growth factors [reviewed in Ref.]. Specific stimulation of the 5-HT 1 and 5-HT 2 receptor subtypes leads to the activation of NF-κB and several MAPKs in many cell types including immune cells. This 5-HTR-mediated, coordinated cross-talk between MAPKs (including p38, MEKK1, ERK, and PI3K/Akt) and NF-κB leads to an intricate fine-tuning of inflammatory responses by the spatio-temporal regulation of cyokine release. The inhibitory or stimulatory effect of GPCR activation on NF-κB and MAPK pathway kinetics is largely depending on the G-proteins that are involved. Psychedelics, acting through mainly 5-HT 1 and 5-HT 2 receptors subtypes, regulate NF-κB and MAPKs via Gα (G i and Gq families), and G βγ proteins. The Gq family of α subunits couples a large number of GPCRs to PLC-β, and many of these have been shown to activate NF-κB. This mechanism is based on the activity of IκBα and the IκB kinases (IKKs), IKKα and IKKβ, as well as the phosphatidylinositol 3-kinase (PI3K) pathway involving the serine/threonine protein kinase Akt. The PLC-β-IP3 axis-mediated release of Ca 2+ from intracellular stores results in the activation of the second messenger conventional protein kinase C (cPKC) (Figure). As mentioned above, this calcium signal can also be attenuated by the activation of sigmar-1, and it is tempting to speculate that sigmar-1 may couple to MAPK and NF-κB signaling and regulate inflammation through this mechanism as well. Several PKC isoforms are known to activate NF-κB, consequently, the Gqmediated activation of NF-κB is the result of PLC-β-controlled convergence of IKK and cPKC signaling. The G i proteins do not activate PLC-β, but use the G βγ class to signal through MAPKs and induce NF-κB phosphorylation and nuclear translocation. Following GPCR activation, G βγ dissociates from Gα and can per se stimulate both PLC-β and PI3K. This allows a direct control of NF-κB transcriptional regulation of chemokines, proinflammatory, and anti-inflammatory cytokines, and thus rendering psychedelics as potentially useful therapeutic tools in a broad range of chronic inflammatory and autoimmune diseases. Another possible mechanism has been raised by recent metaanalyses showing that serotonin signaling could prevent the type I IFN-mediated depressive behavior of HCV patients. The signaling behind this phenomenon has not been uncovered yet; however, it is possible that chronic 5-HTR stimulation may block either the PRR-IRF3/7 or type I IFN receptor pathways. Since both NF-κB and type I IFN signaling contribute to the transcriptional regulation of genes that are involved in cellular proliferation and survival, and many psychedelics exhibit in vitro anti-cancer potential through 5-HTRs, these compounds could be promising candidates in novel therapies of cancer.
Tryptamines are members of a large family of monoamine alkaloids that are widespread in nature and abundant in all the three Kingdoms of life (plants, fungi, and animals). Their main feature is a common indole ring, a backbone that is structurally related to the amino acid tryptophan. This tryptamine backbone designates many biologically active compounds, such as psychedelics and neurotransmitters. To date, our knowledge about the immunomodulatory capacity of tryptamines is quite scarce. DMT is the only member of the family that has been investigated so far. N,N-dimethyltryptamine is related to the neurotransmitter serotonin, the hormone melatonin, and other psychedelic tryptamines, such as bufotenin and psilocin. It is a naturally occurring indole alkaloid that is ubiquitous in plants, such as Diplopterys cabrerana and Psychotria viridis, which are used for the preparation of sacramental psychoactive brews including yage and ayahuasca. In addition to its ubiquitous presence in plant species, DMT has also been detected in animal tissues and is considered to be an endogenous trace amine. The milestones of DMT research were laid down by Szaraand Axelrodwho reported first the psychoactive effects and occurrence of this compound in the human brain. This led to the hypothesis that DMT is an endogenous hallucinogen, and later it was proposed to be a neurotransmitter or neuromodulator. DMT was shown to act as an agonist at several serotonin receptors including 5-HT 1A , 5-HT 2A , and 5-HT 2Cas well as at sigmar-1. The vast majority of the initial research into the reasons for the presence of psychoactive tryptamines in the human body has sought their involvement in mental illness. Until now, very little has been known about the function of DMT in cellular and general physiological processes, and the emphasis of research mostly aimed the understanding of its psychedelic properties (103). Recently, we and others demonstrated that DMT has the capability to modulate immune responses in in vitro human primary cell cultures. In these studies, DMT was shown to act as a non-competitive inhibitor of indoleamine 2,3-dioxygenase (IDO) and as a strong inducer of anti-tumor cytotoxic activity in the co-cultures of human PBMCs and a glioma cell line. Furthermore, DMT and its analog 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) were found to exert potent anti-inflammatory activity through the sigmar-1 in human monocyte-derived dendritic cell (moDC) cultures. MoDCs are key cell types of the mammalian immune system connecting and orchestrating innate and adaptive immune responses as professional antigen-presenting cells (APCs). DMT or 5-MeO-DMT treatment of LPS, polyI:C or pathogen-activated human primary moDCs resulted in a significant inhibition of the secretion of the inflammatory cytokines, IL-1β, IL-6, TNFα, and the chemokine CXCL8/IL-8. In contrast, secreted levels of the anti-inflammatory IL-10 increased markedly following in vitro DMT/5-MeO-DMT administration. DMT and 5-MeO-DMT exhibited the effective inhibitory potential at the level of adaptive immune responses (T helper cell 1 and 17 priming by moDCs), as well (104). These are in line with previous findings showing the immunomodulatory potential of ayahuasca in humans mostly affecting the number and ratio of lymphocyte subpopulations. Notably, the number of circulating NK cells, a cell type involved in anti-viral and anti-cancer immune responses, increased significantly (105, 106). The anti-cancer activity of ayahuasca has already been reviewed in a paper by Schenberg. However, it is important to keep in mind that ayahuasca is a complex decoction that, besides DMT, contains several other components according to the admixture plants used in the making process. Furthermore, ayahuasca can be administered in various ways (single-time, long-term, etc.), thus one should be particularly careful with the study design and interpretation of the data. Nevertheless, ayahuasca consumption in a highly controlled clinical setting emerges as a very promising model for investigating the possible immunomodulatory effects of DMT in humans (107). Importantly, it is possible that the observed anti-inflammatory and immunosuppressive effects may counteract with the anticancer activity, therefore further investigations are needed to elucidate the complex in vivo consequences of DMT administration. The mentioned studies demonstrate and propose new biological roles for DMT, which may act as a systemic endogenous regulator of inflammation and immune homeostasis. According to these new results, DMT and 5-MeO-DMT possess the capability to inhibit the polarization of human moDC-primed CD4 + T helper cells toward the inflammatory Th1 and Th17 effector subtypes in inflammatory settings. This is of particular importance, since Th1 and Th17 cells and the cytokines they secrete are key players in the etiology and symptomatology of many chronic inflammatory and autoimmune diseases of the CNS and other tissues (108, 109). Moreover, the mobilization of innate immune mechanisms is also well established in many psychiatric and neurological disorders. Thus, as a target for future pharmacological investigations, DMT emerges as a potent and promising candidate in novel therapies of peripheral and CNS autoimmune diseases (such as multiple sclerosis or amyotrophic lateral sclerosis) and cancer.
Lysergic acid diethylamide (also know as LSD-25 or lysergide) is a psychedelic substance of the ergoline family. Its pharmacological effects are very complex as it affects several serotonin, as well as all dopamine and adrenoreceptor subtypes. Since most serotonergic psychedelics do not exhibit dopaminergic activity, LSD is quite unique in this regard (110). In humans, LSD mostly affects the 5-HT 1A , 5-HT 2A , 5-HT 2B , and 5-HT 2C serotonin receptor subtypes (111). Furthermore, LSD has a functional selectivity at the 5-HT 2A and 5-HT 2C receptors by specifically activating PLA2 but not PLC (). An early study demonstrated that LSD was able to interfere with antibody production in rabbit (113). In this report, LSD was shown to skew the antibody profile of activated B cells to produce low molecular weight proteins by influencing the process of translation. Excess tryptophan abrogated the effect of LSD on protein synthesis suggesting that the phenomenon may occur at the point of tryptophan insertion during translation. However, the data provided did not adequately support a peptide termination mechanism rather reflected an amino acid analog effect being simulated by LSD (113). These results were in line with the findings of another group showing that in vitro exposure to high LSD concentration (100 µM) could significantly inhibit the proliferation and IL-2, IL-4, and IL-6 secretion of B cells, as well as blocked CD8 + CTL activation. Hundred micromoles of LSD also suppressed NK cell responses in vitro; however, inversely, lower concentrations of LSD (0.0001 and 0.1 µM) augmented NK cell functions. This latter, low concentration can easily be achieved by recreational doses of LSD in humans (111), and therefore may have a significant impact on in vivo anti-tumor and anti-viral immune responses. Human lymphocytes express the 5-HT 1A , 5-HT 2A , 5-HT 2B , and 5-HT 2C subtypes suggesting that LSD may directly modulate cellular functions through these receptors (114, 115). The results obtained so far suggest that LSD may interfere with the elements of the immune system by altering mainly the activity of lymphocytes in mammals. High doses of this substance may alleviate or inhibit adaptive autoimmune responses, while lower doses may positively influence the antiviral or anti-cancer immunity through the modulation of NK cell activation. However, detailed analyses on the complex in vivo effects of LSD on immune functions are yet to be performed.
Phenethylamines (or substituted phenethylamines) are members of a large and diverse group of organic compounds, which derive from phenethylamine itself. Some of them are neurotransmitters, such as dopamine and epinephrine, other members of the family are psychoactive substances (e.g., entactogens or psychedelics), which directly modulate the monoamine neurotransmitter systems, such as the substituted amphetamines, the substituted methylenedioxyphenethylamines, and several other naturally occurring alkaloids. This large family also includes a variety of drug classes, such as dopamine agents (e.g., bupropion), serotonin agents (e.g., the psychedelic 2,5dimethoxy-4-bromoamphetamine), adrenergic agents (e.g., the adrenergic uptake inhibitor methamphetamine), and monoamine oxidase inhibitors (MAOIs) (118). Considering the vast number and diversity of substituted phenethylamines, a comprehensive review about the complex immunological effects of these compounds would exceed the limits of this paper. Therefore, this section focuses on two phenethylamines, DOI and MDMA, which have already been described as potential immunomodulators in higher vertebrate species. These psychedelics have several similarities in their pharmacological action as both of them exhibit a certain degree of agonistic activity at serotonin receptors. DOI acts as a 5-HT 2A , 5-HT 2B , 5-HT 2C , and mGlu2 receptor agoinst (119, 120), while MDMA is primarily a presynaptic releasing agent of serotonin, norepinephrine, and dopamine, but also a weak-to-medium agonist at 5-HT 1 and 5-HT 2 receptor subtypes (121-123). Dimethoxy-4-iodoamphetamine was originally designed and used as a radioligand for the mapping of 5-HT 2 receptors (124, 125). As a 5-HT 2A agonist, DOI was reported to block IL-1β and TNFα release by human PBMCsas well as to inhibit LPS or TNFα-stimulated inducible nitric oxide synthase (iNOS) activity in C6 glioma cells (126, 127). In a landmark paper, the Nichols lab described DOI as an extremely potent inhibitor of TNFα-induced inflammation in rat's primary aortic smooth muscle cell cultures (128). In this report, DOI was shown to inhibit the constitutively high protein-level expression of intracellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), the inflammatory cytokine IL-6, and the activity of NOS, as well as NF-κB signaling. DOI exhibited a fast and effective blocking capacity on the expression and function of TNFα-mediated pro-inflammatory markers within a few hours post-administration suggesting that DOI could be used not only to prevent inflammation but also to treat already ongoing inflammatory tissue damage, such as in allergic asthma (128, 129). The most researched phenethylamine, MDMA, has also been described as an anti-inflammatory and immunosuppressive agent. Early studies reported that MDMA could increase the activity of mouse NK and T helper cells in in vitro cultures at low concentrations (0.0001-1.0 µM). The TNFα production of macrophages and the induction of CTLs were suppressed upon MDMA administration (130). Acute administration of MDMA led to significant immunosuppression by directly decreasing lymphocyte proliferation and blocking the mitogen or LPS-induced cytokine (IL-1β and TNFα) production of T cells in in vivo animal models (131-133). Later, IL-10 was shown to be the critical mediator in these immunosuppressive effects on IL-12 and IFNγ production in mice (134). MDMA has also been demonstrated to interfere with isotype switching blocking the conversion of IgM to IgG2a (135), as well as decreasing the expression of MHC-II and the co-stimulatory molecules, CD40, CD80, ICAM-1 suppressing the T cell-priming capacity of professional APCs (134). Furthermore, several groups reported that MDMA negatively affected in vivo immune responses to various pathogens in animal models (132, 136-140). In agreement with these findings, both acute and chronic MDMA administrations were demonstrated to cause immunosuppression in humans characterized by a significant decrease in T lymphocyte and parallel increase in NK cell functions. Long-term use of MDMA, however, was associated with a decrease in the total number of circulating lymphocyte populations. These alterations also involved a significant decrease in the plasma level of IL-2 and increase of TGF-β in human volunteers (141-144). These results suggest that acute administration of MDMA favors anti-inflammatory immune responses and has a tendency to polarize adaptive immunity toward antibody production. Simultaneously, the activity of NK cells is increased pointing to a complex effect on immune homeostasis. This may reflect to an anti-inflammatory potential of MDMA without significantly decreasing the effectiveness of antiviral or anti-tumor immunity; however, further in vivo studies are needed to unravel the details of this complex immunomodulatory action.
The classical psychedelics discussed in this paper have been shown to exert strong anti-cancer and anti-inflammatory effects through the modulation of innate and adaptive immune processes. The molecular biological background of these effects has not been investigated so far. Two models are proposed here to cover the possible biochemical dynamics of these interactions. On the one hand, (i) regulation may occur through the alteration of the cytokine-pattern of activated cells. The antiinflammatory cytokines, IL-10 and TGFβ, and pro-inflammatory cytokines, TNFα and IFNγ, seem to be key players in this regulation (Figure). On the other hand, (ii) a complex intracellular cross-talk of PRRs, serotonin, and sigma-1 receptors might be involved in the immunomodulatory process. This may happen via the 5-HTR/sigmar-1-mediated modulation of intracellular Ca 2+ levels and the activity of MAPKs and NF-κB, common components of signaling pathways highly involved in cellular proliferation, survival, and inflammation (Figure). Furthermore, interacting PRR and 5-HTR/sigmar-1 pathways may compete for common elements of downstream signaling (e.g., kinases, adaptor proteins), a phenomenon that can also lead to a significant inhibition of one of the interacting partners. A similar mechanism may lead to the preference of a given pathway through kinase or receptor-adaptor bias (145). An interesting contemporary approach to the topic has been carried out by using systems biology, bioinformatics, and biophysics, as tools of better understanding. This approach emphasizes that instead of single cell analyses, one should move toward a more holistic understanding of signaling systems. The meta-network of biological entities is considered to possess both microscopic and macroscopic dynamics as observed in physical sciences. The origin of averaging effects from stochastic responses of a single cell when collected to form a population should also be taken into account (146, 147). It is very likely that the emergence of an average cell deterministic response (e.g., following a PRR and/or 5-HTR stimulus) from single cell stochastic responses complements each other. Consequently, the stochastic fluctuations in the inflammatory response of a single immune cell or a single signaling pathway are necessary to induce probabilistic differentiation from identical cells or interacting pathways of the same receptor family. This might allow multicellular organisms or complex, interacting signaling networks to switch cell fates or states to yield diversity, fine-tuning, and reach the proper response that cannot be achieved by a purely deterministic system. Recent studies of multi-component, non-linear modeling of different TLR pathways verified the success of this idea by identifying cross-talk mechanisms between the MyD88-and TRIF-dependent pathways and led to the concept of signaling flux redistribution (SFR) (149, 150). This proposal is based on the law of conservation where the removal of MyD88 leads to increased activation of the entire alternative TRIF-pathway. Thus, total signaling flux information from a receptor through final downstream gene activation in the network is conserved. The group experimentally validated the SFR theory by using MyD88 -/-and TRAF6 -/-KO mice and their data generated interesting interpretations (150), which may open up new aspects toward the deeper understanding of cellular signaling processes. An important limitation of this double-model hypothesis is that available experimental data supporting the proposed interactions is mostly scarce. Thus, further studies are needed to confirm its relevance in future immunopharmacotherapies, especially as far as translational aspects and human clinical trials are concerned. While PRRs were shown to be crucial for innate and adaptive host defense, their inappropriate activation has been associated with autoimmunity and inflammatory diseases. Psychedelics, by modulating the activity of 5-HT 1 , 5-HT 2 , and sigmar-1 receptors, are potent anti-inflammatory agents. A more complete appreciation of the PRR-5-HTR/sigmar-1 cross-talk and their complex signaling processes would provide important insights into new therapeutic modalities that can either enhance immune responses or inhibit functions to diminish the deleterious effects of uncontrolled inflammation. Thus, these compounds emerge as very promising candidates in many diseases with chronic inflammatory etiology and pathology, such as atherosclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, multiple sclerosis, schizophrenia, depression, and Alzheimer's disease.
Create a free account to open full-text PDFs.
Wallach, J. V. · Medical Hypotheses (2009)
Ray, T. S. · PLOS ONE (2010)
Frecska, E., Szabo, A., Winkelman, M. J. et al. · Translational Neurosciences (2013)
Szabo, A., Kovacs, A., Frecska, E. et al. · PLOS ONE (2014)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2014)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Nau, F., Miller, J., Saravia, J. et al. · American Journal of Physiology (2015)
Papers in Blossom that reference this study
Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Mason, N. L., Szabo, A., Kuypers, K. P. C. et al. · Brain Behavior and Immunity - Health (2023)
Lima da Cruz, R. V., Leão, R. N., Moulin, T. C. · Biorxiv (2023)
Winkelman, M. J., Szabo, A., Frecska, E. · European Neuropsychopharmacology (2023)
Rudin, D., Areesanan, A., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)
Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. et al. · Frontiers in Psychiatry (2022)
Hendricks, P. S., Simonsson, O. · Journal of Psychopharmacology (2022)
Lerer, L. B., Varia, J. · Frontiers in Space Travel (2022)
Mellner, C., Dahlen, M., Simonsson, O. · International Journal of Environmental Research and Public Health (2022)
Jiménez, J. H., Bouso, J. C. · Journal of Psychopharmacology (2022)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Reckweg, J., Uthaug, M. V., Szabo, A. et al. · Journal of Neurochemistry (2022)
Barker, S. A. · Psychopharmacology (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Olson, D. E. · Journal of Neurochemistry (2021)
Matzopoulos, R., Morlock, A., Morlock, R. et al. · MedRvix (2021)
Simonsson, O., Osika, W., Carhart-Harris, R. L. et al. · Scientific Reports (2021)
Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)
Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)
Romach, E. A., Nachliely, M., Moran, O. et al. · Biorxiv (2021)
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Neurotherapeutics (2021)
Thompson, C., Szabo, A. · Immunology Letters (2020)
Kelly, J. R., Crockett, M. T., Alexander, L. et al. · Irish Journal of Psychological Medicine (2020)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
Uthaug, M. V., Lancelotta, R., Szabo, A. et al. · Psychopharmacology (2019)
Kuypers, K. P. C. · Medical Hypotheses (2019)
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)
Dakic, V., Nascimento, J. M., Sartore, R. C. et al. · Scientific Reports (2017)
Ahmad, M., Szabo, A., Kovacs, A. et al. · Frontiers in Neuroscience (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Szabo, A., Frecska, E. · Neural Regeneration Research (2016)